To celebrate Men’s Health Month, the Sexual Medicine Society of North America (#SMSNA18), along with Men’s Health Network, the Congressional Men’s Health Caucus, and hundreds of other local and national organizations, SMSNA will launch an awareness campaign on Twitter and Facebook. You can also bring attention to this campaign by wearing a blue ribbon! #MensHealthMonth #Show Us Your Blue

The goal is to educate the public about the many preventable health problems that affect men and boys, and empower them and their loved ones to move towards a healthier, happier life. Our focus will be on sexual health as it relates to the overall physical and mental well-being of men. Help us get the word out and share these resources to promote men's health!

In 2017. SMSNA partnered with the AUA, the eight AUA Sections, and the urologic community to support comments on the U.S. Preventative Services Task Force (USPSTF) draft recommendations. The USPSTF released its final recommendation statement on Screening for Prostate Cancer and recommended that men ages 55 to 69 make an individual decision about prostate cancer screening with their clinician and for men age 70 or older routine screening is not necessary. To view all the recommendations on the USPSTF's website, click here.

SMSNA recognizes Boston Scientific for their continued partnership with the SMSNA, and their advocacy efforts in the field of sexual medicine. Boston Scientific advocates for patient access to much needed urological procedures and for physician access to the best available technology. A case in point is Boston Scientific’s recent success in protecting the integrity of the Medicare outpatient hospital payment group for Men’s Health procedures, which directly contributed to a 9% increase in the Medicare outpatient hospital payment for Penile Prosthesis and Artificial Urinary Sphincter procedures for 2018.

The SMSNA strongly supports the development of novel erectogenic therapies, given that many men with ED either fail currently available treatments or find them unpalatable. The society, however, recognizes the need for adequately powered, multicenter, randomized, sham/placebo-controlled trials in well-characterized patient populations to ensure that efficacy and safety are demonstrated for any novel ED therapy. The society agrees with the regulatory agency pathway of Phase I, II and III studies to achieve such a goal. Without FDA approval, the use of any novel therapy is considered off-label. The emergence of low intensity shock wave therapy (LiSWT), intracavernous stem cell therapy (SCT), intracavernous platelet rich plasma (PRP) therapy (and other agents such as amniotic fluid) represent a new frontier of investigative restorative therapies for ED treatment. In contrast to existing pharmacologic therapies that treat symptoms, therapies such as LiSWT, SCT, PRP represent potentially restorative modalities based on the concept that they might regenerate erectile tissues.

There exists robust basic science evidence in a variety of animal models (aged, diabetic, cavernous nerve injury) supporting the ability of LiSWT and SCT to improve erectile function. However, to date, there is an absence of robust clinical trial data supporting their efficacy and long-term safety in humans. Furthermore, the precise treatment parameters (energy settings, dosing, frequency of use, and duration of therapy among others) and cell source allowing optimization of these evolving therapies remain as yet, undefined. There exists only a small number of animal studies in a single model (cavernous nerve injury) establishing PRP as a potential erectogenic therapy. At this time, there are no human studies evaluating PRP as an erectogenic therapy.

Although several plausible and scientifically sound mechanisms of action have been proposed to explain how restorative therapies might improve erectile function, rigorous experimental data conclusively validating these mechanisms is currently lacking. This is in part because, unlike conventional pharmacologic therapies which generally have a primary, well-defined target, the mechanism of action of restorative therapies is likely to be complex involving a number of pathways inherent to the regenerative potential of the host. The SMSNA both advocates for and supports the application of high quality research, both pre-clinical and clinical, aimed at better understanding the mechanisms involved, the magnitude and durability of benefit and the long-term safety of restorative therapies.

Thus, given the current lack of regulatory agency approval for any restorative (regenerative) therapies for the treatment of ED and until such time as approval is granted, SMSNA believes that the use of shock waves or stem cells or platelet rich plasma is experimental and should be conducted under research protocols in compliance with Institutional Review Board approval. Patients considering such therapies should be fully informed and consented regarding the potential benefits and risks. Finally, the SMSNA advocates that patients involved in these clinical trials should not incur more than basic research costs for their participation.

The SMSNA will be participating in the 2018 Annual Advocacy Summit, March 12-14, 2018, in Washington, DC. This AUA-led event aims to expand, strengthen and unify the voice of urology on policy matters impacting our practices and patients by bringing together a broad array of stakeholders, including patient advocates and researchers.

The conference will host speakers ranging from urologists to patients, to government employees and members of Congress. It will feature grassroots lobbying training for those new to the process, and will provide opportunities for participants to meet with lawmakers and their staff and some to attend a meeting with officials at agencies such as the Centers for Medicare & Medicaid Services or the National Institutes of Health.

The SMSNA is highlighted in a 45-minute General Session on the program covering the full continuum of care in men’s health, led by Run Wang, MD; Ira Sharlip, MD; Hossein Sadeghi-Nejad, MD; and Arthur Burnett, MD, along with Carlos Basurto, Olivia Basurto, and Ana Fadich.

The AUA is now accepting nominations for the 2018 Early-Career Investigators Workshop. This workshop fosters career development in urologic research by providing participants with a solid foundation for successful grant writing. Activities include one-on-one mentoring sessions with scientific advisors, presentations on navigating federally-funded grant programs and opportunities to directly interact with program officers, mock peer review, presentations on developing a fundable research program and career development presentations. The nomination deadline is March 30, 2018.

SMSNA is pleased to announce the 2018 recipients of the SMSNA Scholars in Sexuality Research Grants Program, which offers young investigators who are interested in sexuality research the opportunity to obtain funding to support their research while engaged in qualifying research in sexuality.

• Manaf Alom, Mayo Clinic, Safety and Efficacy of Collagenase Clostridium Histolyticum in Peyronie's Disease Men with Ventral Curvatures• Himanshu Arora, University of Miami, Nitroso-Redox Imbalance and Secondary Hypogonadism• Lisa Baker, Albert Einstein College of Medicine, Targeting the Microtubule Cytoskeleton to Promote Axon Regeneration and Improve Erectile Function Outcomes after Cavernous Nerve Injury • Peter Dietrich, Medical College of Wisconsin, Evaluation of the Effect of Holmium Enucleation of the Prostate on Erectile Function Using Pre- and Post-operative Penile Doppler Ultrasound• Erin Duralde, University of San Francisco School of Medicine, Mapping Erogenous Anatomy Following Pelvic and Genital Surgery• Michael Odom, East Carolina University, Augmenting Endothelial Nitric Oxide Production to Treat Obesity Induced Erectile Dysfunction Using the Novel Cancer Therapeutic, LB-100• Amit Reddy, Tulane University School of Medicine, The Effects of Prophylactic Compared to Post-surgical Administration of Lipoic Acid on Bilateral Cavernosal Nerve Injury in the Rat Model• Christopher Wu, University of Toronto, Female Sexual Health: Challenges and Solutions in Accessing Care

Travel Awards for Early-Career InvestigatorsThanks to an NIH R13 grant, we are able to offer TRAVEL AWARDS to Early-Career Investigators.

The AUA and Duke Urology are offering travel funds to subsidize a portion of meeting registration, travel and lodging costs associated with attendance to the 2017 Diabetes and Diabetic Uropathy Conference on October 8-9, 2017 at AUA Headquarters in Linthicum, MD. Applications are now being accepted. The applicant must be a student, trainee or early-career investigator within ten (10) years of completing training.

Travel award recipients will receive travel support up to $1,000 per person, to cover the costs to attend the meeting, including economy airfare, parking, ground transportation, meeting registration, and lodging. Duke Urology will manage the travel booking for all awardees, and awardees must follow Duke's official travel guidelines.

All travel awardees will be expected to present a poster of their work during a poster session during the meeting.The application deadline is Wednesday, September 13, 2017.

The Research Scholar Program, the AUA's premier funding opportunity in urologic research, provides $40,000 per year for one- and two-year mentored training for clinical and postdoctoral fellows who are no more than five years beyond completing a doctorate or residency, or early career investigators who are in the first five years after beginning a faculty position. Sponsoring institutions provide matching funds and ensure that the scholar receives adequate research support.

A letter of intent is required and is due by August 11, 2016 at 0 5:00 p.m. Eastern time. The application deadline is September 8, 2016 at 0 5:00 p.m. Eastern time

In 2015 the Food and Drug Administration compelled label changes for all testosterone products marketed in the USA. This label change effectively limited indications for prescribing testosterone. Physicians and patients have been concerned and even confused about diagnosing and treating low testosterone.

The Sexual Medicine Society of North America (www.smsna.org) convened an expert panel to evaluate the existing evidence on low testosterone. In particular, the panel focused on low testosterone associated with low or normal gonadotropin levels. This common clinical scenario accounts for most men with low testosterone and has been named Adult Onset Hypogonadism (AOH). After reviewing the evidence, the panel concluded that men who present with AOH often have other common disease states like diabetes or metabolic syndrome. The panel notes that men with AOH should be counseled regarding the benefits and risks of treatment with testosterone. The panel detailed a rigorous diagnostic process to ensure that men with AOH are accurately identified. In addition, the panel noted that men who are treated with testosterone must be followed regularly for indications of benefit and for adverse events.

Several authors discuss Adult Onset Hypogonadism and how it differs from classic diagnoses of Primary and Secondary Hypogonadism: https://youtu.be/kT7LmsL9_h4.

National Government Services (NGS), the Medicare provider in key States such as NY, MA & IL, has published the final UroLift coverage decision: Prostatic Urethral Lift (PUL) (L36601) that will become effective July 1st, 2016.

The SMSNA is deeply saddened to announce the passing of our colleague, Dr. Graham Jackson on April 28th, 2016. He was a distinguished member of the SMSNA, the International Society for Sexual Medicine (ISSM), and the European Society for Sexual Medicine (ESSM).

Dr. Jackson was a Consultant Cardiologist at London Bridge Hospital, London, UK and BMI Shirley Oaks Hospital in Croydon, Surrey, UK. His NHS medical base was as a senior cardiologist at Guy’s and St Thomas’ Hospitals.

His special interest included the detection, management and treatment of sexual dysfunction in cardiac patients. He was the first cardiologist to establish a clinic specifically for patients with sexual dysfunction and cardiovascular disease in the UK.

For many years, he has been advocating the need for aggressive cardiac risk reduction in men with erectile dysfunction (ED) and no cardiac symptoms, using ED as a means of reducing subsequent cardiac events.

He was a member of the International Society for Sexual Medicine Standards Committee, as well as a prominent speaker at the American Heart Association, the American College of Cardiology , and the British/European Society of Cardiology/World Congress of Cardiology meetings and at many meetings nationally and internationally on sexual problems in cardiac patients.

He will be deeply missed and our thoughts are with his family, friends and colleagues during this difficult time.

The ISSM will provide 15 travel stipends of $ 2000 to attend the ISSM World Meeting on Sexual Medicine in China, September 2016, and 10 scholarships of € 1950 to attend the ESSM School on Sexual Medicine in Hungary, October 2016.

Please find here below the summarized information and link to the details and application form on the website.

15 Travel Stipends to attend the World Meeting on Sexual Medicine in China, September 2016.

The meeting will take place September 22-25, 2016 in Beijing, China.

Fifteen travel stipends in the amount of $ 2000 each are available for attendees of the 20th World Meeting on Sexual Medicine.

Recipients will also receive free registration to the meeting.

In case one is not yet a member of the ISSM, they will receive a one year free ISSM membership (online access to journals only).

Allocation is based on need and applicants must meet specific criteria, including an abstract submission and written proof of a professional degree.

In August 2015, a colloquium of experts commissioned by the Sexual Medicine Society of North America (SMSNA) convened in Washington, DC, to discuss the common clinical scenario of men who present with low testosterone (T) and associated signs and symptoms accompanied by low or normal gonadotropin levels. The Panel consisted of 17 experts in men’s health, sexual medicine, urology, endocrinology, and methodology. The Panel deliberated regarding a rigorous diagnostic process to document signs and symptoms of AOH, the rationale for treatment with T, and a monitoring protocol for T treated patients. The primary purpose of this document is to support health care professionals in the development of a deeper understanding of AOH, particularly in how it differs from classical primary and secondary hypogonadism, and to provide a conceptual framework to guide its diagnosis, treatment, and follow-up.

The International Society for the Study of Women's Sexual Health (ISSWSH), The International Society for the Study of Vulvovaginal Disorders (ISSVD) and the International Pelvic Pain Society (IPPS) have developed an evidence-based consensus among experts, experienced in the diagnosis, evaluation, treatment and/or research of vulvovaginal pain, for appropriate nomenclature and definitions of vulvovaginal pain in women. Their mission was to make these definitions applicable across disciplines and useful in both clinical and research settings and also to serve as the basis of ICD codes for women's sexual health problems. The "2015 Consensus Terminology and Classification of Persistent Vulvar Pain", which has been accepted by all three societies: ISSWSH, ISSVD and IPPS, and the SMSNA Board of Directors has approved the adoption of this document by SMSNA. Please click here for the document.

Tuesday, August 18th, 2015 marked a historic day for Female Sexual Health as the US Food and Drug Administration (FDA) approved Flibanserin, the first drug of its kind in the treatment of female sexual dysfunction.

Addyi, by trade name, is a non-hormonal drug to treat Hypoactive Sexual Desire Disorder (HSDD). HSDD is the persistent loss of desire for sexual activity that causes personal distress. Flibanserin was studied in over 11,000 women and demonstrated a 53% improvement in desire as measured by the Female Sexual Function Index, a doubling of satisfying sexual events and a one-third reduction in distress. Reported side effects include somnolence, dizziness and nausea.

The medication is targeted for women whose low desire is due to biological factors. It is not appropriate for women whose loss of sexual interest is due to relationship factors, depression, or stress. Physicians prescribing Flibanserin and pharmacists dispensing the medication will require certification. The FDA was concerned about possible hypotension with the interaction of Flibanserin in combination alcohol and issued a "black box warning" to physicians and consumers. The consumption of alcohol will be contraindicated in patients taking Flibanserin.

The approval of a safe and effective medication for premenopausal women suffering from low sexual desire is long overdue. SMSNA would like to thank the FDA for recognizing the important unmet medical need in women’s sexual health. In approving this landmark treatment, it will promote further research and drug development in this field.

SMSNA is pleased to announce second annual competition for trainees: Essays in Sexual Medicine and Surgery.

Clinical trainees in medicine, surgery and psychology are eligible (residents, fellows, medical students, graduate students, nursing students and PA students). Manuscripts should also be submitted as abstracts for presentation or poster to the 2015 SMSNA Annual Fall Scientific Meeting. Three prizes of $1500 will be awarded for best essay. The prize categories are: Best Male Sexual Health (clinical, surgical, imaging, research), Best Female Sexual Health (clinical, surgical, imaging, research) and Best Case Report in Sexual Health.

Please note that all manuscripts will be reviewed anonymously. Therefore the first page of the manuscript must contain only the title of the study and no author or contact information should be provided. No information revealing the authors or submitting institutions should be present in the manuscript, which will be sent to reviewers. Any manuscript not submitted electronically or which contain identifying information will not be considered for an essay prize.

Your email must include:

Manuscript Title

Authors

Contact Information

Manuscripts should be sent, as a full paper following the rules of publication on the Journal of Sexual Medicine (JSM) accompanied by an authorization letter for publication to the Essay Prize Review Committee. The winners will be announced at the 2015 SMSNA Annual Fall Scientific Meeting in Las Vegas, NV. All manuscripts, in each category, will be sent to the Journal of Sexual Medicine (JSM) for peer review.

The 2016 Urology Care Foundation Research Scholar Program competition is open! At least 27 awards are available for the 2016 competition, a record high and the leading funding opportunity available through the Urology Care Foundation. Of particular note is an award that is available in sexual medicine research. This award is the inaugural award sponsored through the new Urology Care Foundation/Sexual Medicine Society of North America Research Scholar Endowment Fund which was made possible thanks to the efforts and support of the Sexual Medicine Society of North America and the AUA! The awardee must be a member of the Sexual Medicine Society of North America.

Funding is available for research training in all urologic disease areas and across all research types: basic, translational, clinical, and health services/outcomes. Some awards focus on the following specific research areas:

The 2016 competition will also include awards sponsored by some of the 15 new endowments that have been established over the past two years. We thank the AUA and these organizations for their support of the 2016 competition!

Research Scholar Awards are granted based on the objective evaluation of all aspects of eligibility criteria, scientific review, and the financial portfolio available at the time the grants are finalized by the Urology Care Foundation. The Urology Care Foundation reserves the right for final approval for any/all awards provided through the program.

The Scientific Committee welcomes the submission of abstracts for oral and poster presentations. All abstracts presented at the meeting will be published in the Journal of Sexual Medicine. Submission of abstracts will be accepted only through the website via the procedure as described below:

Abstract Deadline: July 31, 2015

Abstract Prizes5 clinical and 5 basic science prizes of $1000 each will be awarded. A submission is eligible for a prize if:- the presenter/senior author is a resident or within 10 years of finishing training, and;- the presenter is willing to present his/her abstract as a podium presention.

Information is now available online for the 2016 Urology Care Foundation Research Scholars Program! At least 27 awards are available for the 2016 Research Scholar Award competition, a record high and the leading funding opportunity available through the Urology Care Foundation. Importantly, this competition will include the inaugural award supported by the Urology Care Foundation/Sexual Medicine Society of North America Research Scholar Fund! Funding is available for research training in all urologic disease areas and across all research types: basic, translational, clinical, and health services/outcomes. Some awards focus on the following specific research areas:

The 2016 competition will also include awards sponsored by some of the 15 new endowments that have been established over the past two years. We thank the AUA and these organizations for their support of the 2016 competition!

Research Scholar Awards are granted based on the objective evaluation of all aspects of eligibility criteria, scientific review, and the financial portfolio available at the time the grants are finalized by the Urology Care Foundation. The Urology Care Foundation reserves the right for final approval for any/all awards provided through the program.

The online submission portal will open soon. The application deadline is September 9, 2015. A letter of intent is strongly encouraged, but not required, and is due on August 12, 2015. Please direct any questions to grants@auanet.org.

FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link.

The SMSNA is deeply saddened to announce the sudden passing of our colleague Dr. William D. Steers on April 10, 2015.

Dr. Steers was a distinguished member of the SMSNA and the International Society for Sexual Medicine (ISSM).

Dr. Steers, born August 19, 1955, was a Paul Mellon professor and Chair of the Department of Urology at the School of Medicine of the University of Virginia, editor of the Journal of Urology, member of the U.S. Food and Drug Administration's Reproductive Medicine Advisory Panel, President of the American Board of Urology from 2010-2011, initiator of the Charlottesville Men's Four Miler, actively laying the foundation for the Virginia Institute for Men's Health Improvement and Performance.

Our thoughts are with Dr. Steers’ wife, children, and grandchild at this time.

The SMSNA is deeply saddened to announce the sudden passing of our colleague Dr. Andre T. Guay on December 16, 2014.

Dr. Guay was a distinguished member of the SMSNA, the International Society for Sexual Medicine (ISSM), and the International Society for the Study of Women's Sexual Health (ISSWSH).

Dr. Guay was the Director of the Center For Sexual Function (Endocrinology) at Lahey Clinic Northshore in Peabody, Massachusetts, USA. He was also a staff physician in the Department of Endocrinology at the Lahey Clinic Medical Center.

He taught endocrinology and sexual medicine at Lahey for over 40 years and had served on the faculty of Tufts University School of Medicine since 1999.

Earlier this year, the Massachusetts Medical Society honored Dr. Guay with the Men's Health Award, recognizing his contributions to the cause of men's health.

His colleagues described him as a "pioneer and leader in the field of men’s sexual dysfunction" and noted his international reputation, published works, and roles in medical societies.

Dr. Guay received other awards as well, including the Rokitansky Award from Saint Vincent Hospital, the Yearly Research Award from Lahey Clinic, and the Distinguished Service Award in Sexual Medicine from the SMSNA.

He was a Fellow of the American College of Physicians and the American College of Endocrinology.

After completing his bachelor's degree at Boston College, Dr. Guay received his medical degree from the New Jersey College of Medicine and Dentistry in 1968. He conducted his internship and residency in Internal Medicine at Saint Vincent Hospital / University of Massachusetts Medical School. He attended the Mayo Clinic for his specialty training in Endocrinology and Metabolism.

He served in the U.S. Navy from 1974 to 1977 and earned the rank of Lieutenant Commander as a staff physician at the Naval Regional Medical Center in Virginia.

Our thoughts are with Dr. Guay's wife, children, and grandchildren at this time.

On October 27-28th, the Food and Drug Administration will conduct a open public workshop on the topic of Female Sexual Dysfunction in an effort to hear the perspective of patients and providers regarding this unmet medical need. As leaders in sexual medicine, we need to take this opportunity to be politically active.

We have seen first-hand the benefit of medical treatments for male sexual dysfunction over the years. Those same benefits are much needed and deserved for female patients. Here is the chance for each us to engage the FDA.

Take this opportunity to print out and post the announcement (click here to download the PDF) of the FDA Workshop on FSD.

You can show up in person or join this public workshop via webcast. Please encourage your patients to participate.

SMSNA is pleased to announce first annual competition for trainees: Essays in Sexual Medicine and Surgery.

Clinical trainees in medicine, surgery and psychology are eligible (residents, fellows, medical students, graduate students, nursing students and PA students). Manuscripts should also be submitted as abstracts for presentation or poster to the 2014 SMSNA Annual Fall Scientific Meeting. Three prizes of $1500 will be awarded for best essay. The prize categories are: Best Male Sexual Health (clinical, surgical, imaging, research), Best Female Sexual Health (clinical, surgical, imaging, research) and Best Case Report in Sexual Health.

Please note that all manuscripts will be reviewed anonymously. Therefore the first page of the manuscript must contain only the title of the study and no author or contact information should be provided. No information revealing the authors or submitting institutions should be present in the manuscript, which will be sent to reviewers. Any manuscript not submitted electronically or which contain identifying information will not be considered for an essay prize.

Your email must include:

Manuscript Title

Authors

Contact Information

Manuscripts should be sent, as a full paper following the rules of publication on the Journal of Sexual Medicine (JSM) accompanied by an authorization letter for publication to the Essay Prize Review Committee. The winners will be announced at the 2014 SMSNA Annual Fall Scientific Meeting in Miami, FL. All manuscripts, in each category, will be sent to the Journal of Sexual Medicine (JSM) for peer review.

As a professional society dedicated to the effective and safe treatment of individuals with sexual dysfunction and men’s health overall, the Sexual Medicine Society of North America is aware of recent concerns regarding cardiovascular risks associated with the use of testosterone therapy. This concern stems from two journal articles, one published in November 2013 in the Journal of the American Medical Association (1), and the other published in January 2014 in the journal, Plos One (2). Neither of these reports was a planned experimental study with control groups and defined goals. Instead these were retrospective analyses of data collected for other reasons. These types of analyses are prone to bias and error, and results are often irreproducible (3). For this reason, this type of study is generally not used for medical decision-making, although in some cases these may prompt further investigation with an experimental study.

First, on behalf of the society's leadership and staff, I wish to extend my very best wishes to you and your family for a happy and prosperous year 2014. The past year has been an unforgettable year for the Sexual Medicine Society of North America, and we all have been kept quite active in meeting the needs and objectives of members of our society and preparing for a variety of challenges to come. As we approach yet another year's end, I wish to take a moment to convey some highlights and important developments.

State of the Society The Sexual Medicine Society of North America (SMSNA) stands as strong as ever as the premier society in North America committed to promoting the sexual health of men and women. We are delighted to continue our strong relationship with our international affiliate, the International Society for Sexual Medicine, as we acknowledge our collaborative mission to serve our patients worldwide with clinical and research excellence in sexual medicine.

Society Meetings We successfully held our 19th Annual Fall Scientific Meeting in New Orleans, Louisiana just a few weeks ago, giving tremendous thanks to many colleagues who sponsored, organized, and conducted this meeting. For those who attended, I am sure you will agree that we displayed an incredible scientific and social program that will be hard to beat for future fall meetings! The attendance at the meeting was also phenomenal, with more than 570 attendees. Thank you for your attendance and support of this meeting. We now look forward to holding an exciting scientific meeting in partnership with the Society of Urologic Prosthetic Surgeons this spring preceding the annual American Urological Association meeting in Orlando, Florida. We hope that you will attend. Right around the corner will be our 20th Annual Fall Scientific Meeting in Miami Beach, Florida. So plan ahead to be there too!

Journals The publication of our best scientific work and other academic communications is now achieved by the availability of a family of three official journals of the International Society for Sexual Medicine. These are the Sexual Medicine Reviews edited by Culley Carson, the online only Sexual Medicine edited by Alan Shindel, and our flagship The Journal of Sexual Medicine, which has just completed its 10th year of existence under the editorship of Irwin Goldstein. The latter journal is undergoing a transition as Irwin Goldstein prepares to step down and transfer stewardship to John Mulhall. A supreme level of gratitude goes out to Irwin and his editorial team for outstanding service brought to our societies in this capacity. We can certainly anticipate that journalistic prowess will continue with the energy and commitment of the new editors.

The Year Ahead In the coming year, the SMSNA will build on its strengths and continue to advance our field with further educational, scientific and health policy initiatives. A top priority is to elevate our trainee fellowship program with scholarships and research awards in support of the best and the brightest young minds wishing to join and contribute to sexual medicine. We welcome all to renew your memberships, welcome new members, and invigorate us all with your ongoing ideas, input and involvement.

Our Services

About SMSNA

Established in 1994, our objective has been to promote, encourage, and support the highest standards of practice, research, education, and ethics in the study of the anatomy, physiology, pathophysiology, diagnosis, and treatment...